Document text
Principal Investigator: JEFFREY J DESTEFANO
Organization: UNIV OF MARYLAND, COLLEGE PARK
Fiscal Year: 2022
Award: $193,125
Funding agency: National Institute of Allergy and Infectious Diseases
The impact of SARS-CoV-2 on public health and the global economy cannot be overstated. As of September
28, 2020, 33,224,222 cases and 999,298 deaths worldwide have been linked to this emergent virus. This
staggering number continues to grow, with the United States baring disproportionately high rates of morbidity
and mortality. The virus targets the respiratory tract, leading to a wide range of clinical outcomes including mild
upper respiratory tract illness and severe viral pneumonia with respiratory failure. To date, four SARS-CoV-2
vaccine candidates have entered phase 3 clinical trials and a massive parallel effort has been undertaken to
repurpose already FDA-approved drugs for the treatment of COVID-19 or identify compounds with potential
therapeutic activity. Despite this effort, remdesivir remains the only approved (with emergency use authorization)
direct-acting antiviral for the treatment of COVID-19. Of critical importance: there is currently no vaccine or
SARS-CoV-2-specific therapy approved for the prevention or treatment of disease. Furthermore, multiple
antivirals may be required to avoid the rapid emergence of resistant SARS-CoV-2 strains. Thus, the development
of novel therapeutics targeting SARS-CoV-2 are urgently needed. Infection requires interaction between the viral
surface protein, spike (S), and a host protein, ACE2, that is expressed on type II alveolar cells and ciliated cells
in the human airway epithelium (HAE), making these cells potentially vulnerable to infection. Thus, our goal is to
develop a novel therapeutic that blocks this interaction between spike (on the virus) and ACE2 (on the host cell)
to prevent infection and ameliorate disease. Aptamers are short nucleic acid-based sequences that bind with
high affinity to their targets. Among other applications, aptamers have been shown to have potent antiviral activity
and low toxicity in cell culture. While aptamers were originally made with RNA and DNA, Xeno-Nucleic Acids
(XNA: nucleotide analogs with altered sugar, base, or phosphate backbones) have emerged as important new
substrates and XNA aptamers often demonstrate enhanced target binding and greater stability compared to RNA
and DNA aptamers. Thus, we hypothesize that aptamer technology, and specifically XNA aptamers, can be
leveraged to inhibit spike-ACE2 interaction and propose to establish an innovative, in vitro screening platform
that can serve to assess the efficacy of such aptamers, or other novel therapeutics, in blocking infection. This
platform will utilize SARS-CoV-2 pseudoparticles (allowing work under Biosafety Level 2 containment) and a
physiologically-relevant in vitro model of human airway epithelium that recapitulates the mucosal surface of the
airway in vivo. Aptamers will also be tested using live virus infections of culture cells (Biosafety Level 3). This
work is highly significant given the immediate need for novel therapeutics against SARS-CoV-2. Further, the
development of a high-throughput, pseudoparticle-based assay to assess viral entry in a relevant culture system
will have broad applications for additional drug screens and / or studies that aim to further understand SARSCoV-
2 virus-host interactions at the level of particle uptake.
Terms: <2019 novel corona virus><2019 novel coronavirus><2019-nCoV><2019-nCoV vaccine><ACE2><Affinity><Antibodies><Antiviral Agents><Antiviral Drugs><Antivirals><Aptamer Technology><Assay><Base Sequence><Binding><Bioassay><Biochemical><Biologic Assays><Biological Assay><Biosensor><COVID-19><COVID-19 therapeutics><COVID-19 therapy><COVID-19 treatment><COVID-19 vaccine><COVID-19 virus><COVID19><COVID19 therapeutics><COVID19 therapy><COVID19 treatment><COVID19 vaccine><COVID19 virus><CV-19><CV19><Cell Body><Cell Culture Techniques><Cells><Cessation of life><Chemicals><Clinical><CoV-2><CoV2><Collaborations><Containment><Coronaviridae><Coronavirus><DNA><DNA Molecular Biology><Death><Deoxyribonucleic Acid><Development><Diagnostic><Disease><Disorder><Drug Screening><Drug Therapy><ELISA><Enzyme-Linked Immunosorbent Assay><Evaluation><Evolution><FDA EUA><FDA Emergency Use Authorization><FDA approved><Fatality rate><Feedback><Food and Drug Administration EUA><Food and Drug Administration Emergency Use Authorization><Future><GS-5734><Generations><Goals><Human><In Vitro><Infection><Infection prevention><Letters><Ligands><Link><MERS><MERS coronavirus disease><MERS-CoV disease><Membrane Protein Gene><Membrane Proteins><Membrane-Associated Proteins><Middle East Respiratory Syndrome><Middle East Respiratory Syndrome CoV disease><Middle East Respiratory Syndrome coronavirus disease><Middle Eastern Respiratory Syndrome><Middle Eastern Respiratory Syndrome CoV disease><Middle Eastern Respiratory Syndrome coronavirus disease><Modeling><Modern Man><Modernization><Modification><Molecular Biology><Molecular Interaction><Morbidity><Morbidity - disease rate><Mucosa><Mucosal Tissue><Mucous Membrane><Non-Polyadenylated RNA><Nucleic Acids><Nucleotide Sequence><Nucleotides><Outcome><Persons><Pharmacotherapy><Phase 3 Clinical Trials><Phase III Clinical Trials><Phosphates><Physiologic><Physiological><Prevent infection><Prevention><Property><Proteins><Public Health><Pulmonary Body System><Pulmonary Organ System><RNA><RNA Gene Products><RNA Nucleases><RNase><Race><Racial Group><Racial Stocks><Resistance><Respiratory Epithelium><Respiratory Failure><Respiratory System><Respiratory Tracts><Respiratory tract structure><Ribonuclease Family Protein><Ribonucleases><Ribonucleic Acid><SARS Virus><SARS corona virus><SARS corona virus 2><SARS coronavirus><SARS-Associated Coronavirus><SARS-CO-V2><SARS-COVID-2><SARS-CoV><SARS-CoV-1><SARS-CoV-2><SARS-CoV-2 therapeutics><SARS-CoV-2 therapy><SARS-CoV-2 treatment><SARS-CoV-2 vaccine><SARS-CoV2><SARS-CoV2 vaccine><SARS-Related Coronavirus><SARS-associated corona virus 2><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-coronavirus-2 therapeutics><SARS-coronavirus-2 vaccine><SARS-related corona virus 2><SARS-related coronavirus 2><SARSCoV2><Severe Acute Respiratory Coronavirus><Severe Acute Respiratory Coronavirus 2><Severe Acute Respiratory Distress Syndrome CoV 2><Severe Acute Respiratory Distress Syndrome Corona Virus 2><Severe Acute Respiratory Distress Syndrome Coronavirus 2><Severe Acute Respiratory Syndrome CoV 2><Severe Acute Respiratory Syndrome CoV 2 vaccine><Severe Acute Respiratory Syndrome Virus><Severe Acute Respiratory Syndrome corona virus><Severe Acute Respiratory Syndrome coronavirus><Severe Acute Respiratory Syndrome-associated coronavirus 2><Severe Acute Respiratory Syndrome-related coronavirus 2><Severe acute respiratory syndrome associated corona virus 2><Severe acute respiratory syndrome corona virus 2><Severe acute respiratory syndrome coronavirus 2><Severe acute respiratory syndrome coronavirus 2 therapeutics><Severe acute respiratory syndrome coronavirus 2 vaccine><Severe acute respiratory syndrome related corona virus 2><Societies><Spinal Column><Spine><Structure of respiratory epithelium><Surface><Surface Proteins><System><Testing><Therapeutic><Toxic effect><Toxicities><Type II Pneumocyte><United States><Upper respiratory tract><Vaccines><Veklury><Vertebral column><Viral><Viral Diseases><Viral Pneumonia><Virus><Virus Diseases><Virus Inhibitors><Work><Wuhan coronavirus><airway epithelium><alveolar type II cell><angiotensin converting enzyme 2><angiotensin converting enzyme II><anti-viral agents><anti-viral compound><anti-viral development><anti-viral drug development><anti-viral drugs><anti-viral medication><anti-viral therapeutic><anti-viral therapeutic development><anti-viral therapy development><anti-virals><antiviral compound><antiviral development><antiviral drug development><antiviral medication><antiviral therapeutic><antiviral therapeutic development><antiviral therapy development><aptamer><backbone><base><biological sensor><cell culture><cell cultures><corona virus><corona virus disease 2019><corona virus disease 2019 vaccine><coronavirus disease 2019><coronavirus disease 2019 therapeutics><coronavirus disease 2019 therapy><coronavirus disease 2019 treatment><coronavirus disease 2019 vaccine><coronavirus disease 2019 virus><coronavirus disease-19><coronavirus disease-19 vaccine><coronavirus disease-19 virus><coronavirus infectious disease-19><develop a vaccine><develop vaccines><developing anti-viral agent><developing anti-viral drug><developing anti-viral therapeutic><developing anti-viral therapy><developing antiviral agent><developing antiviral drug><developing antiviral therapeutic><developing antiviral therapy><development of a vaccine><developmental><drug treatment><emergency use authorization><enzyme linked immunoassay><hCoV19><human model><human pathogen><immunogenicity><improved><in vitro Model><in vivo><innovate><innovation><innovative><inorganic phosphate><lung failure><model of human><mortality><nCoV2><new drug target><new drug treatments><new druggable target><new drugs><new pharmacotherapy target><new therapeutic target><new therapeutics><new therapy><new therapy target><next generation therapeutics><novel><novel drug target><novel drug treatments><novel druggable target><novel drugs><novel pharmacotherapy target><novel therapeutic target><novel therapeutics><novel therapy><novel therapy target><nucleic acid sequence><nucleotide analog><pandemic><pandemic disease><particle><phase III protocol><pulmonary failure><rapid assay><rapid test><rapid tests><receptor binding><receptor bound><remdesivir><resistant><respiratory virus><screening><severe acute respiratory syndrome coronavirus 2 therapy><severe acute respiratory syndrome coronavirus 2 treatment><severe acute respiratory syndrome-CoV><small molecule><sugar><tech development><technology development><therapeutic target><therapeutics against COVID-19><therapeutics against COVID19><therapeutics against SARS-CoV-2><therapeutics against SARS-coronavirus-2><therapeutics against Severe acute respiratory syndrome coronavirus 2><therapeutics against coronavirus disease 2019><therapeutics for novel coronavirus><tool><treat COVID-19><treat COVID19><treat SARS-CoV-2><treat coronavirus disease 2019><treat severe acute respiratory syndrome coronavirus 2><upper airway tract><uptake><vaccine against 2019-nCov><vaccine against SARS-CoV-2><vaccine against SARS-CoV2><vaccine against SARS-coronavirus-2><vaccine against Severe Acute Respiratory Syndrome CoV 2><vaccine against Severe acute respiratory syndrome coronavirus 2><vaccine candidate><vaccine development><vaccine for novel coronavirus><viral infection><viral inhibitor><virus host interaction><virus infection><virus-induced disease>